Skip to main navigation
Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Biography

Thomas Ricks

Director
  • Member of the Compensation Committee
  • Chair of the Audit Committee

Investor Tools

  • Email Alerts
  • Investor FAQs
  • RSS Feeds
  • Contact Us
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone-icon

+1.240.243.8000

 

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
email-icon

info@senseibio.com

 

© 2021 Sensei Biotherapeutics, Inc. All Rights Reserved.

Legal

  • Privacy Policy

Social Links

Go to Top